Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2020

01-01-2020 | Metastasis | Preclinical Study

Risk stratification system for groups with a low, intermediate, and high risk of subsequent distant metastasis and death following isolated locoregional recurrence of breast cancer

Authors: Young Joo Lee, Heeseung Park, Cheol Min Kang, Sung-chan Gwark, Sae Byul Lee, Jisun Kim, Il Yong Chung, Beom Seok Ko, Hee Jeong Kim, Sung-Bae Kim, Seung Do Ahn, Gyungyub Gong, Byung Ho Son, Sei-Hyun Ahn, Jong Won Lee

Published in: Breast Cancer Research and Treatment | Issue 2/2020

Login to get access

Abstract

Purpose

This study aimed to identify prognostic factors for long-term outcomes among patients with isolated locoregional recurrence (ILRR) of breast cancer as their first failure event. Many prognostic tools have been developed to inform systemic treatment choices in the adjuvant setting, but tools for predicting post-ILRR prognosis are scarce.

Methods

A total of 495 patients who experienced ILRR after primary surgery at the Asan Medical Center between 1989 and 2008 were included. All patient information and tumor characteristics at the initial surgery were retrieved from our retrospectively collected database, and ILRRs were categorized as local recurrence or regional recurrence (RR). Distant metastasis-free survival (DMFS), breast cancer-specific survival (BCSS), and overall survival post-ILRR were calculated.

Results

The median follow-up from the ILRR was 65 months (range 1–249 months), and the 5-year post-ILRR DMFS rate was 58.9%. We found three factors—lymph node metastasis, a disease-free interval < 30 months, and RR as the ILRR type—that were independent prognostic factors for both DMFS [hazard ratio (HR) = 2.08, 1.60, and 1.59; P < 0.001, 0.002, and 0.003, respectively] and BCSS (HR = 2.28, 1.99, and 1.48; P < 0.001, < 0.001, and 0.016, respectively) post-ILRR. Patients were classified into four groups according to the presence these three prognostic indicators: the low-, intermediate-, high-, and extremely high-risk groups. The 5-year post-ILRR DMFS rates were 79.4%, 68.1%, 47.6%, and 36.0%, respectively.

Conclusions

This risk stratification system for subsequent distant metastases after ILRR can be used to make more informed decisions regarding prognosis-based local or systemic management strategies.
Literature
2.
go back to reference Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, Geyer CE Jr, Wickerham DL, Costantino JP, Wolmark N (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol 27:2466–2473. https://doi.org/10.1200/jco.2008.19.8424 CrossRefPubMedPubMedCentral Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, Geyer CE Jr, Wickerham DL, Costantino JP, Wolmark N (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol 27:2466–2473. https://​doi.​org/​10.​1200/​jco.​2008.​19.​8424 CrossRefPubMedPubMedCentral
4.
go back to reference Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE Jr, Jeong JH, Tan-Chiu E, Fisher B, Wolmark N (2006) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24:2028–2037. https://doi.org/10.1200/jco.2005.04.3273 CrossRefPubMed Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE Jr, Jeong JH, Tan-Chiu E, Fisher B, Wolmark N (2006) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24:2028–2037. https://​doi.​org/​10.​1200/​jco.​2005.​04.​3273 CrossRefPubMed
5.
go back to reference Montagna E, Bagnardi V, Rotmensz N, Viale G, Renne G, Cancello G, Balduzzi A, Scarano E, Veronesi P, Luini A, Zurrida S, Monti S, Mastropasqua MG, Bottiglieri L, Goldhirsch A, Colleoni M (2011) Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol 23:324–331. https://doi.org/10.1093/annonc/mdr129 CrossRefPubMed Montagna E, Bagnardi V, Rotmensz N, Viale G, Renne G, Cancello G, Balduzzi A, Scarano E, Veronesi P, Luini A, Zurrida S, Monti S, Mastropasqua MG, Bottiglieri L, Goldhirsch A, Colleoni M (2011) Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol 23:324–331. https://​doi.​org/​10.​1093/​annonc/​mdr129 CrossRefPubMed
7.
go back to reference Wapnir IL, Khan A (2019) Current strategies for the management of locoregional breast cancer recurrence. Oncology (Williston Park) 33:19–25 Wapnir IL, Khan A (2019) Current strategies for the management of locoregional breast cancer recurrence. Oncology (Williston Park) 33:19–25
8.
go back to reference Waeber M, Castiglione-Gertsch M, Dietrich D, Thurlimann B, Goldhirsch A, Brunner KW, Borner MM (2003) Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol 14:1215–1221. https://doi.org/10.1093/annonc/mdg347 CrossRefPubMed Waeber M, Castiglione-Gertsch M, Dietrich D, Thurlimann B, Goldhirsch A, Brunner KW, Borner MM (2003) Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol 14:1215–1221. https://​doi.​org/​10.​1093/​annonc/​mdg347 CrossRefPubMed
9.
go back to reference Wapnir IL, Price KN, Anderson SJ, Robidoux A, Martin M, Nortier JWR, Paterson AHG, Rimawi MF, Lang I, Baena-Canada JM, Thurlimann B, Mamounas EP, Geyer CE Jr, Gelber S, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S (2018) Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: final analysis of the CALOR trial. J Clin Oncol 36:1073–1079. https://doi.org/10.1200/jco.2017.76.5719 CrossRefPubMedPubMedCentral Wapnir IL, Price KN, Anderson SJ, Robidoux A, Martin M, Nortier JWR, Paterson AHG, Rimawi MF, Lang I, Baena-Canada JM, Thurlimann B, Mamounas EP, Geyer CE Jr, Gelber S, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S (2018) Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: final analysis of the CALOR trial. J Clin Oncol 36:1073–1079. https://​doi.​org/​10.​1200/​jco.​2017.​76.​5719 CrossRefPubMedPubMedCentral
15.
go back to reference de Bock GH, van der Hage JA, Putter H, Bonnema J, Bartelink H, van de Velde CJ (2006) Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer 42:351–356. https://doi.org/10.1016/j.ejca.2005.10.006 CrossRefPubMed de Bock GH, van der Hage JA, Putter H, Bonnema J, Bartelink H, van de Velde CJ (2006) Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer 42:351–356. https://​doi.​org/​10.​1016/​j.​ejca.​2005.​10.​006 CrossRefPubMed
19.
go back to reference Gentilini O, Botteri E, Veronesi P, Sangalli C, Del Castillo A, Ballardini B, Galimberti V, Rietjens M, Colleoni M, Luini A, Veronesi U (2012) Repeating conservative surgery after ipsilateral breast tumor reappearance: criteria for selecting the best candidates. Ann Surg Oncol 19:3771–3776. https://doi.org/10.1245/s10434-012-2404-5 CrossRefPubMed Gentilini O, Botteri E, Veronesi P, Sangalli C, Del Castillo A, Ballardini B, Galimberti V, Rietjens M, Colleoni M, Luini A, Veronesi U (2012) Repeating conservative surgery after ipsilateral breast tumor reappearance: criteria for selecting the best candidates. Ann Surg Oncol 19:3771–3776. https://​doi.​org/​10.​1245/​s10434-012-2404-5 CrossRefPubMed
Metadata
Title
Risk stratification system for groups with a low, intermediate, and high risk of subsequent distant metastasis and death following isolated locoregional recurrence of breast cancer
Authors
Young Joo Lee
Heeseung Park
Cheol Min Kang
Sung-chan Gwark
Sae Byul Lee
Jisun Kim
Il Yong Chung
Beom Seok Ko
Hee Jeong Kim
Sung-Bae Kim
Seung Do Ahn
Gyungyub Gong
Byung Ho Son
Sei-Hyun Ahn
Jong Won Lee
Publication date
01-01-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05469-5

Other articles of this Issue 2/2020

Breast Cancer Research and Treatment 2/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine